Clinical trials: Psychosis
Schizophrenia, Iloperidone
Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia
The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.
- Conditions
- Schizophrenia, Iloperidone, Efficacy
- Trial name
- NCT01623713
- Testing
- iloperidone, Risperidone
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia
Long-term Extension Trial of Asenapine in Subjects With Schizophrenia (Study P06125)
This is a multi-site, randomized fixed-flexible dose long-term study of asenapine in participants with schizophrenia. The first six weeks of the study will be double-blind and the remainder of the study will be open label.
- Trial name
- NCT01142596
- Testing
- Asenapine
- Volunteers
- 201 people
- Sponsor
- Organon and Co
Schizophrenia
A Study of the Effect of Food on the Pharmacokinetics of ER OROS Paliperidone in Healthy Japanese Volunteers
The purposes of this study are to evaluate the effect of food on the pharmacokinetics of extended-release (ER) OROS paliperidone in healthy Japanese adults and to assess the safety and tolerability.
- Trial name
- NCT00892320
- Testing
- ER OROS paliperidone
- Volunteers
- 20 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychotic Disorders
A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders
The primary purpose of the study is to compare therapy with antipsychotic medication (antipsychotic monotherapy or antipsychotic combination) versus no antipsychotic medication, and antipsychotic monotherapy versus antipsychotic…
- Trial name
- NCT05633108
- Testing
- No Intervention
- Where
- United Kingdom
- Volunteers
- 579,728 people
- Sponsor
- Eisai Co., Ltd.
Schizophrenia
Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
The purpose of the protocol is to evaluate the efficacy of olanzapine compared with Aripiprazole in patients with schizophrenia.
- Trial name
- NCT00088049
- Testing
- Olanzapine, Aripiprazole
- Where
- 24 sites in United States
- Volunteers
- 560 people
- Sponsor
- Eli Lilly and Company
Schizophrenic Disorder
SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia
The purpose of this 6-week study is to determine whether treatment with Seroquel® Sustained Release (SR) is more effective than placebo in the treatment of acute schizophrenia.
- Trial name
- NCT00206115
- Testing
- Seroquel Sustained Release (SR), Seroquel Immediate Release (IR)
- Where
- 31 sites in Bulgaria, Greece and 6 more
- Volunteers
- 535 people
- Sponsor
- AstraZeneca
Schizophrenia
Randomized Withdrawal Study in Patients With Schizophrenia
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
- Trial name
- NCT06961968
- Testing
- iloperidone
- Where
- 22 sites in United States
- Volunteers
- 400 people
- Sponsor
- Vanda Pharmaceuticals
Schizophrenia
A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase
A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.
- Trial name
- NCT04825860
- Testing
- SEP-363856 50 mg, SEP-363856 75 mg
- Where
- 54 sites in China, Japan and 2 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Bipolar Disorder, Schizophrenia
Non Interventional Study In Bipolar Disorder And Schizophrenia With Zeldox
Investigation of the impact of Zeldox on metabolic parametres in patients with bipolar disorder or with schizophrenia and impact of the treatment for the quality of life
- Trial name
- NCT00538629
- Testing
- no intervention
- Volunteers
- 471 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
- Trial name
- NCT06572449
- Testing
- KarXT
- Where
- 6 sites in United States
- Volunteers
- 173 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
A Study Using Rapid Acting Intramuscular Olanzapine in Agitated Patients With Schizophrenia
To investigate dose-response of Rapid Acting Intramuscular Olanzapine in Agitated Patients with Schizophrenia
- Trial name
- NCT00316238
- Testing
- olanzapine-RAIM
- Where
- 15 sites in Japan
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Agitation Associated With, Alzheimer's Disease
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type
- Conditions
- Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder
- Trial name
- NCT01922258
- Testing
- Brexpiprazole, OPC-34712
- Where
- 70 sites in United States, Bulgaria and 7 more
- Volunteers
- 270 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder
This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its effect, if any, on the brain.
- Trial name
- NCT00892021
- Testing
- NSA-789
- Where
- United States
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia
Efficacy Study of Paliperidone to Evaluate Subjective Change in Well-being and Drug Attitude in Schizophrenic Participants
The purpose of this study is to evaluate improvement and efficacy of paliperidone extended-release for subjective well-being and drug attitudes of participants, when switching from oral antipsychotics in participants with…
- Trial name
- Power (NCT00784238)
- Testing
- Paliperidone
- Where
- 11 sites in South Korea
- Volunteers
- 289 people
- Sponsor
- Janssen Korea, Ltd., Korea
Schizophrenia
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia
To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia
- Trial name
- NCT03238326
- Testing
- Brexpiprazole
- Where
- 57 sites in United States, France and 8 more
- Volunteers
- 295 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00731549)
- Testing
- Aripiprazole IM Depot
- Where
- 214 sites in United States, Argentina and 26 more
- Volunteers
- 1,081 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE US (NCT01432444)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection
- Where
- 124 sites in United States, Canada
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Multicenter, Open-label, Safety and Tolerability Study
This will be a multicenter, 52 week, open label study to assess the safety and tolerability of oral OPC-34712 (1 to 6 mg) as monotherapy in adult patients with schizophrenia. The study will be conducted on an outpatient basis.
- Trial name
- STEP 210 (NCT01649557)
- Testing
- OPC-34712
- Where
- 68 sites in United States, Bulgaria and 10 more
- Volunteers
- 244 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Bipolar Disorder
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
- Conditions
- Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
- Trial name
- NCT06229210
- Testing
- Lumateperone
- Where
- 65 sites in United States, Colombia and 1 more
- Volunteers
- 300 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
Huperzine for Cognitive and Functional Impairment in Schizophrenia
Huperzine is a natural plant product with procognitive properties in patients with Alzheimer's disease. Cognitive difficulties hamper functioning in schizophrenia as well.
- Trial name
- NCT00963846
- Testing
- huperzine 0.2 mg BID, huperzine 0.4 mg BID, huperzine 0.8 mg BID
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Biomedisyn Corporation